Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its…
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvictoâ„¢ (lutetium (177Lu)…
DATROWAY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
No Difference in Transplant Outcomes Seen for Patients Unlikely to Find a Matched Unrelated Donor When a Donor Search Prognosis Strategy is Used
Published in the Journal of Clinical Oncology, results showed no difference in…
Former Google Exec Outlines the High-Stakes Battle Behind Google Reviews on Maury Blackman’s Great Minds Think Data
Brad Wetherall, former Director for Google Business Profile, details survival tactics for…
Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted…
Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…